Autotransplants in leukemia: current state, future progress.
Autotransplants in leukemia are controversial; their rationale and results have been questioned. Here we consider several issues central to this debate: (1) Are there convincing data to suggest that more intensive therapy increases cures? (2) Are results post-autotransplant a consequence of the transplant, or do they reflect subject-selection and time-to-treatment (time censoring) biases? (3) Does leukemia relapse after an autotransplant develop from persisting leukemia cells in the subject or the graft? (4) Do autotransplants using hematopoietic stem cells from different sources have distinct outcomes? (5) Are immune-mediated anti-leukemia mechanisms likely to prevent relapse after autotransplants? and (6) Can comparably intensive therapy be given without an autotransplant?
Department of Medicine, UCLA School of Medicine 90024-1678.
R P
RP
Gale
A
A
Butturini
P
P
Reizenstein
D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000276:immunology; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D014182:Transplantation, Autologous; D014430:Twins, Monozygotic
D005047:Etoposide; D003520:Cyclophosphamide